Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 5/20 | 0.77 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.59 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | IDO1 | P14902 | 4/20 | 0.61 |
| ▸ | AGXT | P21549 | 2/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951818 | 0.97 | MAOB (0.73) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| SCHEMBL8755 | 0.97 | MAOB (0.73) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| Iodide SCHEMBL28780684 | 0.95 | MAOB (0.70) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| Ammonia Solution, Strong SCHEMBL9173570 | 0.95 | MAOB (0.70) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| Bromide SCHEMBL31513712 | 0.95 | MAOB (0.70) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| Hydrochloric Acid SCHEMBL7011298 | 0.93 | MAOB (0.68) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| Methyl Alcohol SCHEMBL28283803 | 0.93 | MAOB (0.68) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| SCHEMBL5828695 | 0.91 | MAOB (0.70) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| SCHEMBL920324 | 0.91 | ST14 (0.68) | MAOBTAAR1IDO1AGXTSLC6A4 | |
| Hypochlorous Acid SCHEMBL10950049 | 0.91 | MAOB (0.66) | MAOBTAAR1IDO1AGXTSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114524747-A | Capsaicin derivative and preparation method and application thereof | 中国中医科学院中药研究所 | 2022-05-24 | — | — | CN | claimed |
| US-10059654-B2 | Composition containing 3-chloro-4-methoxybenzylamine hydrochloride, and method for producing same | AIR WATER INC. (JP) | 2018-08-28 | — | — | US | claimed |
| US-20180029974-A1 | COMPOSITION CONTAINING 3-CHLORO-4-METHOXYBENZYLAMINE HYDROCHLORIDE, AND METHOD FOR PRODUCING SAME | AIR WATER INC (JP) | 2018-02-01 | — | — | US | claimed |
| EP-3138830-A1 | COMPOSITION CONTAINING 3-CHLORO-4-METHOXYBENZYLAMINE HYDROCHLORIDE, AND METHOD FOR PRODUCING SAME | Air Water Inc. (JP) | 2017-03-08 | — | — | EP | claimed |
| US-20170044091-A1 | COMPOSITION CONTAINING 3-CHLORO-4-METHOXYBENZYLAMINE HYDROCHLORIDE, AND METHOD FOR PRODUCING SAME | AIR WATER INC. (JP) | 2017-02-16 | — | — | US | claimed |
| CN-118771989-A | Method for catalyzing hydrosilation reduction of amide into amine by using tridentate nitrogen ligand manganese complex | 浙江工业大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-115304578-B | Organic-inorganic hybrid perovskite material, preparation method and application thereof, and electronic equipment | 天津大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-115304578-A | Organic-inorganic hybrid perovskite material, preparation method and application thereof, and electronic device | 天津大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-114524747-B | Capsaicin derivative and preparation method and application thereof | 中国中医科学院中药研究所 | 2022-07-15 | — | — | CN | disclosed |
| CN-114524747-A | Capsaicin derivative and preparation method and application thereof | 中国中医科学院中药研究所 | 2022-05-24 | — | — | CN | disclosed |
| EP-3350170-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-01-26 | — | — | EP | disclosed |
| CN-108290879-B | Heteroaryl compounds as IRAK inhibitors and uses thereof | 默克专利有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-0853626-A1 | SUBSTITUTED PHOSPHINIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| US-5714599-A | Process for the preparation of ste specific 1'-spiro-nucleosides | NOVARTIS CORPORATION (US) | 1998-02-03 | — | — | US | disclosed |
| US-5641882-A | Intermediates for the preparation of 1',1'-disubstituted and 1'-spiro-nucleosides | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| WO-1997009335-A1 | SUBSTITUTED PHOSPHINIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| EP-0625144-A1 | PYRIDONE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993015056-A1 | PYRIDONE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1993-08-05 | — | — | WO | disclosed |
| US-4507499-A | N-(4-Hydroxybenzyl)-3,4,5-trimethoxybenzamide and method for producing trimethobenzamide chlorohydrate | FRANCIS S.P.A. (IT) | 1985-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059654-B2 | Composition containing 3-chloro-4-methoxybenzylamine hydrochloride, and method for producing same | CMBL, HAO2, CPNE4 | MAOB 10/4885SLC6A4 2037/4885CA2 364/4885 |
| US-20170044091-A1 | COMPOSITION CONTAINING 3-CHLORO-4-METHOXYBENZYLAMINE HYDROCHLORIDE, AND METHOD FOR PRODUCING SAME | CMBL, HAO2, CPNE4 | MAOB 10/4885SLC6A4 2037/4885CA2 364/4885 |
| US-20180029974-A1 | COMPOSITION CONTAINING 3-CHLORO-4-METHOXYBENZYLAMINE HYDROCHLORIDE, AND METHOD FOR PRODUCING SAME | CMBL, HAO2, CPNE4 | MAOB 10/4885SLC6A4 2037/4885CA2 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.